The European Medicines Agency (EMA) has reversed its long-held stance on releasing studies on drug side effects after pressure from the European Ombudsman.
The London-based agency, which evaluates drugs in the EU, on Wednesday (11 August) said that it would issue data on anti-acne medication Roaccutane produced by pharma giant Roche in the coming weeks.
An Irish man, whose son committed suicide after taking Roaccutane, is currently suing Roche over the drug, which has been linked...
Back our independent journalism by becoming a supporting member
Already a member? Login here